• 1. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 2. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 3. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 4. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 5. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431

Comprehensive Analysis of 8-Bromo-3-chloroimidazo[1,2-a]pyridine (CAS No. 1289261-79-5): Properties, Applications, and Industry Trends

The heterocyclic compound 8-bromo-3-chloroimidazo[1,2-a]pyridine (CAS 1289261-79-5) has garnered significant attention in pharmaceutical and agrochemical research due to its unique structural features. As a fused bicyclic system, this molecule combines the imidazo[1,2-a]pyridine scaffold with strategic halogen substitutions at the 3- and 8-positions, making it a versatile intermediate for drug discovery programs targeting various biological pathways.

Recent literature highlights the growing importance of halogenated imidazopyridines in medicinal chemistry, particularly in the development of kinase inhibitors and GPCR modulators. The presence of both bromine and chlorine substituents in CAS 1289261-79-5 provides distinct electronic and steric properties that influence molecular recognition and binding affinity. Researchers are particularly interested in how these halogen atoms affect the compound's metabolic stability and membrane permeability - key parameters in modern drug design.

From a synthetic chemistry perspective, 8-bromo-3-chloroimidazo[1,2-a]pyridine serves as a valuable building block for palladium-catalyzed cross-coupling reactions. The bromine at position 8 readily participates in Suzuki, Stille, and Buchwald-Hartwig couplings, while the 3-chloro substituent offers additional sites for functionalization through nucleophilic aromatic substitution. This dual reactivity makes the compound particularly useful for generating diverse chemical libraries in high-throughput screening campaigns.

The thermal stability and crystallinity of 1289261-79-5 have been subjects of recent investigations, especially in the context of solid-state pharmaceutical formulations. Differential scanning calorimetry studies reveal a melting point range between 180-185°C, with good compatibility with common excipients. These physicochemical properties are crucial for researchers exploring the compound's potential in co-crystal engineering and salt formation strategies.

In material science applications, the imidazo[1,2-a]pyridine core of this compound has shown promise in organic electronic devices. The conjugated π-system, when incorporated into larger molecular architectures, can facilitate charge transport in organic field-effect transistors (OFETs). The halogen atoms in 8-bromo-3-chloroimidazo[1,2-a]pyridine provide anchoring points for further structural elaboration toward functional materials with tailored optoelectronic properties.

Analytical characterization of CAS 1289261-79-5 typically involves a combination of HPLC (typically >98% purity), mass spectrometry (ESI-MS m/z calculated for C7H4BrClN2: [M+H]+ 248.93), and comprehensive NMR profiling (1H, 13C, 2D correlations). The compound's stability under various pH conditions has been systematically evaluated, showing remarkable resilience in acidic media but requiring protection from strong nucleophiles in basic environments.

Current market trends indicate growing demand for halogenated heterocycles like 8-bromo-3-chloroimidazo[1,2-a]pyridine, driven by pharmaceutical companies expanding their pipelines of targeted therapies. The compound's molecular weight (247.48 g/mol) and lipophilicity (calculated cLogP ~2.3) make it particularly attractive for CNS drug discovery, where balanced physicochemical properties are essential for blood-brain barrier penetration.

Environmental and safety assessments of 1289261-79-5 suggest standard handling procedures for halogenated organic compounds, including the use of personal protective equipment and proper ventilation. While not classified as acutely toxic, prudent laboratory practices recommend minimizing exposure through inhalation or skin contact during scale-up operations.

Future research directions for 8-bromo-3-chloroimidazo[1,2-a]pyridine derivatives may explore their potential in photopharmacology, where the bromine substituent could be replaced with photoactive groups to create light-responsive drug candidates. The compound's robust synthetic accessibility positions it as a key starting material for such innovative approaches in precision medicine.

From a regulatory standpoint, CAS 1289261-79-5 currently faces no usage restrictions in major pharmaceutical markets, making it an attractive intermediate for global drug development projects. However, researchers should stay informed about evolving guidelines concerning halogenated compounds as environmental regulations continue to develop worldwide.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)